Epigenetic mechanisms in breast cancer therapy and resistance

Liliana Garcia-Martinez, Yusheng Zhang, Yuichiro Nakata, Ho Lam Chan, Lluis Morey

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance.

Original languageEnglish (US)
Article number1786
JournalNature communications
Issue number1
StatePublished - Dec 2021
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Epigenetic mechanisms in breast cancer therapy and resistance'. Together they form a unique fingerprint.

Cite this